Literature DB >> 34315922

Monocyte-dependent co-stimulation of cytokine induction in human γδ T cells by TLR8 RNA ligands.

Ruben Serrano1, Christoph Coch2, Christian Peters1, Gunther Hartmann2, Daniela Wesch1, Dieter Kabelitz3.   

Abstract

Human Vγ9Vδ2 T cells recognize pyrophosphates produced by microbes and transformed cells and play a role in anti-infective immunity and tumor surveillance. Toll-like receptors (TLR) are pattern recognition receptors in innate immune cells which sense microbial structures including nucleic acids. Given that γδ T cells are in clinical development for application in cellular cancer immunotherapy and TLR ligands have potent adjuvant activity, we investigated the co-stimulatory role of selected TLR ligands in γδ T-cell activation. Here we have used recently described RNA ligands for TLR7 and TLR8 together with Vγ9Vδ2 T-cell specific pyrophosphate antigens to analyze the rapid cytokine induction in Vδ2 T cells as well as the accessory cell requirements. While TLR8- as well as TLR7/8-specific RNA did not induce IFN-γ in Vδ2 T cells on their own, they provided strong co-stimulation for Vδ2 T cells within peripheral blood mononuclear cells in the presence of additional T-cell receptor activation. In contrast, TLR7 ligands were ineffective. Purified γδ T cells did not directly respond to TLR8 co-stimulation but required the presence of monocytes. Further experiments revealed a critical role of IL-1β and IL-18, and to a slightly lesser extent of IL-12p70, in the co-stimulation of Vδ2 T cells by TLR8 and TLR7/8 RNA ligands. Results of intracellular cytokine expression were validated by ELISA analysis of cytokines in cell culture supernatants. The cell context-dependent adjuvant activity of TLR8 and TLR7/8 RNA ligands described here might be important for the future optimization of γδ T-cell based cancer immunotherapy.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34315922     DOI: 10.1038/s41598-021-94428-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  60 in total

1.  Identification of the complete expressed human TCR V gamma repertoire by flow cytometry.

Authors:  T Hinz; D Wesch; F Halary; S Marx; A Choudhary; B Arden; O Janssen; M Bonneville; D Kabelitz
Journal:  Int Immunol       Date:  1997-08       Impact factor: 4.823

2.  Structural features of nonpeptide prenyl pyrophosphates that determine their antigenicity for human gamma delta T cells.

Authors:  C T Morita; H K Lee; H Wang; H Li; R A Mariuzza; Y Tanaka
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

3.  Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli.

Authors:  M Hintz; A Reichenberg; B Altincicek; U Bahr; R M Gschwind; A K Kollas; E Beck; J Wiesner; M Eberl; H Jomaa
Journal:  FEBS Lett       Date:  2001-12-07       Impact factor: 4.124

4.  Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma.

Authors:  E T Creagan; A J Schutt; D L Ahmann; S J Green
Journal:  Cancer Treat Rep       Date:  1982-05

5.  Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

Authors:  Christelle Harly; Yves Guillaume; Steven Nedellec; Cassie-Marie Peigné; Hannu Mönkkönen; Jukka Mönkkönen; Jianqiang Li; Jürgen Kuball; Erin J Adams; Sonia Netzer; Julie Déchanet-Merville; Alexandra Léger; Thomas Herrmann; Richard Breathnach; Daniel Olive; Marc Bonneville; Emmanuel Scotet
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

6.  Nontraumatic ghost cell glaucoma--a case report.

Authors:  A M Mansour; J Chess; R Starita
Journal:  Ophthalmic Surg       Date:  1986-01

Review 7.  Mevalonate Metabolism in Immuno-Oncology.

Authors:  Georg Gruenbacher; Martin Thurnher
Journal:  Front Immunol       Date:  2017-12-01       Impact factor: 7.561

8.  Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

Authors:  Anke J Roelofs; Marjo Jauhiainen; Hannu Mönkkönen; Michael J Rogers; Jukka Mönkkönen; Keith Thompson
Journal:  Br J Haematol       Date:  2008-11-07       Impact factor: 6.998

9.  Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.

Authors:  Hans-Jürgen Gober; Magdalena Kistowska; Lena Angman; Paul Jenö; Lucia Mori; Gennaro De Libero
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

10.  Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.

Authors:  Yan Xu; Zheng Xiang; Mohammed Alnaggar; Léonce Kouakanou; Jiawei Li; Junyi He; Jiashuang Yang; Yi Hu; Yan Chen; Li Lin; Jianlei Hao; Jingxia Li; Jibing Chen; Man Li; Qingling Wu; Christian Peters; Qinghua Zhou; Jianshuang Li; Yingqing Liang; Xiaohua Wang; Baohui Han; Meili Ma; Dieter Kabelitz; Kecheng Xu; Wenwei Tu; Yangzhe Wu; Zhinan Yin
Journal:  Cell Mol Immunol       Date:  2020-09-16       Impact factor: 22.096

View more
  3 in total

1.  Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function.

Authors:  Huaishan Wang; Hui Chen; Shujing Liu; Jie Zhang; Hezhe Lu; Rajasekharan Somasundaram; Robin Choi; Gao Zhang; Lingling Ou; John Scholler; Shifu Tian; Liyun Dong; Guo Yeye; Lili Huang; Thomas Connelly; Ling Li; Alexander Huang; Tara C Mitchell; Yi Fan; Carl H June; Gordon B Mills; Wei Guo; Meenhard Herlyn; Xiaowei Xu
Journal:  J Immunother Cancer       Date:  2021-12       Impact factor: 13.751

2.  Systemic Administration of the TLR7/8 Agonist Resiquimod (R848) to Mice Is Associated with Transient, In Vivo-Detectable Brain Swelling.

Authors:  Natalie May Zahr; Qingyu Zhao; Ryan Goodcase; Adolf Pfefferbaum
Journal:  Biology (Basel)       Date:  2022-02-10

3.  Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells.

Authors:  Ruben Serrano; Marcus Lettau; Michal Zarobkiewicz; Daniela Wesch; Christian Peters; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2022-02-01       Impact factor: 8.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.